Congress demands PBMs expose hidden drug markups and rebate schemes
H.R. 2450 — Prescription Drug Transparency and Affordability Act · Filed by Kristen McDonald Rivet (D-MI) · 3 cosponsors · Introduced Mar 27, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires pharmacy benefit managers (PBMs) to provide detailed, transparent reports to health plans and insurers about drug pricing, rebates, and fees at least every six months. The reports must show what plans pay for drugs, what pharmacies receive, rebate amounts, patient out-of-pocket costs, and any conflicts of interest (like PBM-owned pharmacies). Large employers and plans can request quarterly reports. The goal is to expose hidden markups and rebate practices that may inflate drug costs for patients and plans.
Why we flagged it
The bill's core function is regulatory transparency—it mandates detailed reporting by PBMs to expose pricing, rebates, and conflicts of interest. It is not a price-control or subsidy measure, but a disclosure and oversight mechanism designed to increase market accountability.
What the text implies
- PBMs may face significant compliance costs to build reporting systems, which could be passed to plans and ultimately patients through higher premiums.
- Detailed rebate and pricing data disclosed to plans may reveal competitive strategies, potentially reducing PBM negotiating leverage with manufacturers.
The full analysis lists 5 implications of this text.
Who stands to gain
large employers and self-insured plans (better negotiating data); independent pharmacies (exposure of PBM-affiliated pharmacy advantages); health plan consultants and brokers (demand for data analysis services)